SavedAdd your journal

Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2007 / Cilt: 15 - Sayı: 3

The effect of the presence of autocrine motility factor receptor on survival in patients with stage I epidermoid lung cancer

Akciğer evre I epidermoid karsinomlu olgularda otokrin hareket faktör reseptörü varlığınının sağkalıma etkisi

Kamil KAYNAK
Ezel ERŞEN
Ahmet DEMİRKAYA
Berrak AKGÖZ
Büge ÖZ
Murat KARA
Pages
233–237
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall survival in patients with AMFR expression was significantly worse than those without AMFR expression (p=0.052).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: We aimed to investigate the existence of autocrine motility factor receptor (AMFR) and its effect on survival in patients with stage I squamous cell carcinoma.
📊
Key Findings & Data:Methods: The study included 30 patients (23 males, 7 females; mean age 60±10 years; range 33 to 77 years) with stage I squamous cell carcinoma of the lung.
💡
Conclusion & Impact:The overall survival in patients with AMFR expression was significantly worse than those without AMFR expression (p=0.052).
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: We aimed to investigate the existence of autocrine motility factor receptor (AMFR) and its effect on survival in patients with stage I squamous cell carcinoma. Methods: The study included 30 patients (23 males, 7 females; mean age 60±10 years; range 33 to 77 years) with stage I squamous cell carcinoma of the lung. None of the patients received chemotherapy or radiotherapy before or after surgery. The mean follow-up period was 48±11 months. The chi-square test was used for comparison of variables. The cumulative survival rates were calculated by the Kaplan-Meier method and the significance was assessed by the log-rank test. The effects of AMFR and clinical factors on survival were assessed by univariate and multivariate analyses using Cox’s proportional hazard model.Results: Six tumors (20%) showed positive staining for AMFR. The overall survival in patients with AMFR expression was significantly worse than those without AMFR expression (p=0.052). Multivariate analysis showed AMFR expression (p<0.016) and older age (p<0.015) as independent prognostic factors on poor survival.Conclusion: Expression of AMFR can be a useful marker for the follow-up of patients with cancer and for metastatic potential of tumors. However, further studies are required to determine its value for adjuvant therapy.

Özet

Giriş: Çalışmamızda, evre I skuamöz hücreli karsinomlu hastalarda otokrin hareket faktör reseptörü (OHFR) varlığı ve bunun sağkalım ile ilişkisi araştırıldı. Çalışma planı: Çalışmaya akciğerde evre I skuamöz hücre karsinomu saptanan 30 hasta (23 erkek, 7 kadın; ort. yaş 60±10; dağılım 33-77) alındı. Olguların hiçbiri ameliyat öncesi veya sonrasında kemoterapi veya radyoterapi görmemişti. Ameliyat sonrasında hastalar ortalama 48±11 ay takip edildi. Parametrelerin kıyaslanmasında ki-kare testi kullanıldı. Sağkalım analizi Kaplan-Meier yöntemiyle yapıldı ve istatistiksel farklar log-rank testi ile doğrulandı. Sağkalım üzerine OHFR ve klinik özelliklerin etkisini değerlendirmek için tekdeğişkenli ve çokdeğişkenli Cox regresyon analiz modeli kullanıldı.Bulgular: Altı hastada (%20) OHFR için boyama pozitif bulundu. Tüm sağkalım, OHFR pozitif olan hastalarda negatif olanlara kıyasla anlamlı derecede kötü bulundu (p=0.052). Çokdeğişkenli analizde OHFR pozitifliği (p<0.016) ve ileri yaş (p<0.015) sağkalım üzerine olumsuz etki yapan bağımsız prognostik faktörler olarak bulundu.Sonuç: Kanser hastalarının takibinde ve metastatik potansiyelin değerlendirilmesinde OHFR yararlı bir belirteç olabilir; ancak, OHFR’nin adjuvan terapiye bir kılavuz olması için ek çalışmalara ihtiyaç vardır.

🔖

Cite This Article

KAYNAK, K., ERŞEN, E., DEMİRKAYA, A., AKGÖZ, B., ÖZ, B., KARA, M. (2022). The effect of the presence of autocrine motility factor receptor on survival in patients with stage I epidermoid lung cancer. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 15 - Sayı: 3, 233–237. https://ajindex.com/articles/425167

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Auerbach O, Stout Ap, Hammond Ec, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961;265:253-67
  2. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9
  3. Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, et al. Postrecurrent survival of patients with non-smallcell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994;108:158-61
  4. Volk T, Geiger B, Raz A. Motility and adhesive properties of high- and low metastatic murine neoplastic cells. Cancer Res 1984;44:811-24
  5. Partin AW, Schoeniger JS, Mohler JL, Coffey DS. Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A 1989;86:1254-8
  6. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986;83:3302-6
  7. Rosen EM, Goldberg ID. Protein factors which regulate cell motility. In Vitro Cell Dev Biol 1989;25:1079-87
  8. Nakamori S, Watanabe H, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, et al. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer 1994;74:1855-62
  9. Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rübben H, et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 1994;54:3120-3
  10. Maruyama K, Watanabe H, Shiozaki H, Takayama T, Gofuku J, Yano H, et al. Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Int J Cancer 1995;64:316-21
  11. Hirono Y, Fushida S, Yonemura Y, Yamamoto H, Watanabe H, Raz A. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. Br J Cancer 1996;74:2003-7
  12. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7
  13. Nabi IR, Watanabe H, Raz A. Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res 1990;50:409-14
  14. Silletti S, Watanabe H, Hogan V, Nabi IR, Raz A. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 1991;51:3507 11
  15. Watanabe H, Carmi P, Hogan V, Raz T, Silletti S, Nabi IR, et al. Pu